An investigational immunomodulator gel significantly improved malodor and measures related to pain and quality of life for ...
VT-1953 treatment significantly reduced malignant fungating wound-associated malodor (primary endpoint) (P<0.001). Patients also reported significant improvements in lesion pain (P<0.001) and Quality ...
CAMBRIDGE, MA, UNITED STATES, January 22, 2025 /EINPresswire.com/ -- • VT-1953 treatment reduces malignant fungating wound-associated malodor over a 14 day period ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback